Welcome to our dedicated page for Materialise SEC filings (Ticker: MTLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Materialise NV (MTLS) SEC filings page brings together the company’s official disclosures as a foreign private issuer under the Securities Exchange Act of 1934. Materialise files Form 6‑K reports to provide English‑language versions of press releases, financial results, and other information that it makes public in Belgium or through other regulatory channels.
In its 6‑K filings, Materialise reports detailed quarterly financial results, including revenue by segment for Materialise Medical, Materialise Software, and Materialise Manufacturing, gross profit, operating result, net profit, cash and debt positions, and non‑IFRS measures such as EBIT, EBITDA, Adjusted EBIT, and Adjusted EBITDA. These filings also explain how non‑IFRS metrics are calculated and why management uses them to evaluate performance.
Beyond earnings, Materialise uses 6‑K reports to disclose capital markets and governance developments. Recent filings describe the company’s additional listing of its ordinary shares on Euronext Brussels, the publication of a listing prospectus, and shareholder approvals of a new text of the articles of association, including the introduction of double voting rights for certain shares. Other filings outline an up to EUR 30 million ADS buyback program over Nasdaq, subject to specific conditions, and provide information about extraordinary general shareholders’ meetings and proposed amendments to the articles of association.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are paired with AI‑powered summaries that highlight the main points of each document. Investors can quickly see what changed in the latest 6‑K, how segment performance evolved, and what new authorizations or listings have been announced. For deeper analysis, users can review the full text of the filings, including financial tables and explanatory notes, while using AI insights to navigate complex financial and legal language more efficiently.
Materialise NV reported stronger fourth-quarter 2025 results, with revenue up 6.8% to 70,164 kEUR and net profit rising to 6,206 kEUR from 2,907 kEUR. Gross margin improved to 58.1%, while operating profit swung to 3,111 kEUR from a loss a year earlier.
Growth was driven by the Materialise Medical segment, whose Q4 revenue rose 16.3% and Adjusted EBITDA margin reached 35.2%. For full year 2025, revenue was broadly stable at 267,633 kEUR, but net profit declined to 7,716 kEUR from 13,406 kEUR, mainly due to weaker financial result and foreign exchange impacts. Cash and cash equivalents increased to 133,918 kEUR, and Adjusted EBITDA margin improved slightly to 12.1%.
Materialise NV reported higher profitability for Q4 2025 and modest full-year growth, led by strong performance in its Medical segment. Fourth-quarter revenue rose 6.8% to 70,164 kEUR and net profit more than doubled to 6,206 kEUR, supported by a jump in adjusted EBITDA to 9,524 kEUR.
For full year 2025, revenue was broadly flat at 267,633 kEUR, but adjusted EBITDA edged up to 32,386 kEUR and adjusted EBIT to 10,601 kEUR. Medical revenue grew 15.4% with a 32.0% adjusted EBITDA margin, while Software revenue declined and Manufacturing contracted, producing a negative margin.
The company ended 2025 with 133,918 kEUR of cash and cash equivalents and a net cash position of 70,805 kEUR. For 2026, it guides revenue to 273,000–283,000 kEUR and expects adjusted EBIT between 10,000 and 12,000 kEUR, driven by continued Medical growth and ongoing Manufacturing restructuring.
Materialise NV reported progress on its previously announced share buyback program. During the period from 9 to 13 February 2026, the company repurchased 52,222 shares at an average price of 4.67 EUR, for a total of 243,734 EUR, via Nasdaq’s central order book.
Since the program started on 26 January 2026, Materialise has bought back 163,345 shares for 754,080 EUR (895,012 USD), equal to 0.3% of its total shares outstanding. The company now holds 163,345 of its own shares and plans to keep publishing weekly updates on its investor website.
Materialise NV reports progress on its share buy-back program of up to EUR 30 million. From 2 to 6 February 2026, the company repurchased 66,945 shares on Nasdaq at an average price of 4.54 EUR per share, for a total of 303,785 EUR (358,738 USD).
Since the program started on 26 January 2026, Materialise has bought back 111,123 shares for 510,346 EUR (605,421 USD), equal to 0.2% of total shares outstanding. The company now holds 111,123 own shares and publishes weekly updates on its investor website.
Materialise NV reports initial progress on its share buy-back program of up to EUR 30 million. Between 26 and 30 January 2026, the company repurchased 44,178 shares on Nasdaq at an average price of EUR 4.68 per share, for a total of EUR 206,562.
These purchases represent 0.1% of total shares outstanding, and Materialise now holds the same number of own shares. All trades were executed via the central order book, with no cross or block trades, under a discretionary mandate to an independent financial intermediary.
Materialise NV reports that its ordinary shares have begun trading on Euronext Brussels, in addition to its existing Nasdaq listing of American depositary shares representing ordinary shares. The additional listing and trading on Euronext Brussels commenced on November 20, 2025.
At an extraordinary shareholders’ meeting on November 14, 2025, shareholders adopted a new text of the company’s articles of association, which became effective upon the Euronext Brussels listing. The company emphasizes that this information does not constitute an offer of securities, that no public offering is or will be made, and that no offer of securities has been or will be made in the United States. A prospectus for the Euronext Brussels listing was approved by the FSMA on November 18, 2025.
Materialise NV reported that it has published a listing prospectus in connection with an additional listing of its ordinary shares on Euronext Brussels. This new listing is intended to complement the existing Nasdaq listing of its American depositary shares, which represent ordinary shares of the company. The prospectus was prepared under European Union and Belgian regulations and is provided as an exhibit to the report, giving investors in Europe a locally listed line of ordinary shares alongside the U.S.-listed ADSs.
Materialise NV plans an additional listing of its ordinary shares on Euronext Brussels alongside its Nasdaq ADSs. The company stated that no shares will be offered and no capital will be raised in connection with the Brussels listing. The Board also approved an up to EUR 30 million ADS buyback over Nasdaq, subject to publication of shareholder authorization in the Belgian State Gazette and completion of the Brussels listing.
Materialise will hold an extraordinary general shareholders’ meeting on November 14, 2025 at 17:00 CET to consider share capital movements and buyback authorization, updates to the articles (including introducing double voting rights for certain shares), remuneration policy approval, appointing the statutory auditor for sustainability assurance, and confirming board composition. Admission to trading requires an FSMA-approved prospectus and is subject to market conditions, with no guarantee the listing will occur.
Materialise NV (MTLS) reported Q3 2025 results with total revenue of 66,259 kEUR, down 3.5% year over year. Net profit was 1,848 kEUR and the operating result was 2,522 kEUR.
Performance varied by segment: Medical grew 10.3% to 33,296 kEUR, while Manufacturing fell 17.1% to 22,677 kEUR and Software declined 7.4% to 10,286 kEUR. Gross margin held essentially steady at 56.8%. Adjusted EBITDA was 8,428 kEUR versus 9,895 kEUR, and Adjusted EBIT margin was 4.4% compared to 6.4% a year ago.
Operating cash flow was 10,359 kEUR and capital expenditures were 5,288 kEUR. Cash and cash equivalents were 132,022 kEUR at September 30, 2025, against gross debt of 64,278 kEUR, resulting in a net cash position of 67,744 kEUR. Basic EPS was 0.03.